This study is aimed at investigating the effect of PPIs on gastroesophageal varices in liver cirrhosis. Half of participants will receive PPI, while the other half will receive a placebo.
PPIs can inhibit parietal cell H+/K+-ATPase and reduce secretion of gastric acid. PPIs can promote platelet aggregation and stabilize the formation of fibrin thrombosis by maintaining the high pH environment in the stomach and inactivating pepsin. The effect of PPIs on ulcerative upper gastrointestinal bleeding was confirmed but it is not clear whether PPIs is applicable in esophagogastric variceal bleeding whose etiology and bleeding position are different from ulcerative upper gastrointestinal bleeding. There is lack of consensus and sufficient evidences to support to use PPIs in esophagogastric variceal bleeding in cirrhotic patients universally. Nevertheless, the use of PPIs in liver cirrhotic patients with gastroesophageal varices is common.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
106
Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
Department of Gastroenterology,Qilu Hospital,Shandong University
Jinan, Shandong, China
Variceal Bleeding Events
The primary endpoint was variceal bleeding, which was defined as hematemesis or melena from endoscopically proven GEVs, in the absence of any other lesion that might explain the bleeding.
Time frame: 8 weeks
Mortality
Prognosis of esophagogastric variceal bleeding.
Time frame: 8 weeks
Adverse Eventsafter Endoscopic Therapy
Advers events caused by endoscopic therapy, including chest pain, dysphagia, fever and so on
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.